Cytokinetics Inc’s filing revealed that its EVP, Chief Commercial Officer Callos Andrew unloaded Company’s shares for reported $0.14 million on Mar 06 ’25. In the deal valued at $43.27 per share,3,341 shares were sold. As a result of this transaction, Callos Andrew now holds 64,434 shares worth roughly $2.79 million.
Then, Malik Fady Ibraham sold 8,228 shares, generating $356,026 in total proceeds. Upon selling the shares at $43.27, the EVP Research & Development now owns 105,394 shares.
Before that, Blum Robert I sold 16,970 shares. Cytokinetics Inc shares valued at $737,177 were divested by the President & CEO at a price of $43.44 per share. As a result of the transaction, Blum Robert I now holds 364,181 shares, worth roughly $15.77 million.
Citigroup initiated its Cytokinetics Inc [CYTK] rating to a Buy in a research note published on February 07, 2025; the price target was $86. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in late January with a ‘”a Buy”‘ rating. RBC Capital Mkts began covering CYTK with “an Outperform” recommendation on November 08, 2024. Goldman revised its rating on August 13, 2024. It rated CYTK as “a Neutral” which previously was an “a Buy”.
Price Performance Review of CYTK
On Monday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -0.28% to $43.31. Over the last five days, the stock has gained 0.98%. Cytokinetics Inc shares have fallen nearly -7.93% since the year began. Nevertheless, the stocks have fallen -35.24% over the past one year. While a 52-week high of $75.71 was reached on 01/27/25, a 52-week low of $40.53 was recorded on 02/12/25. SMA at 50 days reached $46.75, while 200 days put it at $52.01.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 42.53, which if violated will result in even more drops to 41.76. On the upside, there is a resistance level at 44.42. A further resistance level may holdings at 45.54. The Relative Strength Index (RSI) on the 14-day chart is 42.05, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.62, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.85%. Stochastics %K at 17.44% indicates the stock is a buying.
